Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: SCAN measured global readiness to provide diagnostics and treatments for NET patients in terms of awareness, availability, quality and affordability.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Van Genechten D
Authors: Van Genechten D, McDonnell M, Rodien-Louw C, Dureja S, Leyden S,
Keywords: Neuroendocrine Tumours, Survey, Earlier diagnosis,
Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Dureja S
Authors: Dureja S, Sen I, Pant V, Thak P,
Keywords: Targeted alpha therapy, TAT, PRRT, neuroendocrine tumors, beta refractory,
Introduction: Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE is gaining acceptance as safe and effective therapy for inoperable neuroendocrine tumors (NET). A radiosensitizing chemotherapeutic drug -capecitabine, the prodrug of 5-Flourouracil, is included in the protocol to further enhance therapeutic efficacy.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Dureja S
Authors: Dureja S, Thakral P, Pant V, Pallavi U, Vindhya M,
Keywords: PRRT, radiosensitizer,